172 related articles for article (PubMed ID: 29273105)
1. The Utility and Validity of the Alopecia Areata Symptom Impact Scale in Measuring Disease-Related Symptoms and their Effect on Functioning.
Mendoza TR; Osei J; Duvic M
J Investig Dermatol Symp Proc; 2018 Jan; 19(1):S41-S46. PubMed ID: 29273105
[TBL] [Abstract][Full Text] [Related]
2. Development of the alopecia areata symptom impact scale.
Mendoza TR; Osei JS; Shi Q; Duvic M
J Investig Dermatol Symp Proc; 2013 Dec; 16(1):S51-2. PubMed ID: 24326557
[TBL] [Abstract][Full Text] [Related]
3. Analysis of alopecia areata surveys suggests a threshold for improved patient-reported outcomes.
Renert-Yuval Y; Correa da Rosa J; Garcet S; Pavel AB; Bares J; Chima M; Hawkes JE; Gilleaudeau P; Sullivan-Whalen M; Singer GK; Krueger JG; Guttman-Yassky E
Br J Dermatol; 2022 Oct; 187(4):539-547. PubMed ID: 35656793
[TBL] [Abstract][Full Text] [Related]
4. Impact of cyclosporin treatment on health-related quality of life of patients with alopecia areata.
Lai VWY; Chen G; Sinclair R
J Dermatolog Treat; 2021 Mar; 32(2):250-257. PubMed ID: 31389731
[TBL] [Abstract][Full Text] [Related]
5. Validation of the Alopecia Areata Patient Priority Outcomes (AAPPO) Questionnaire in Adults and Adolescents with Alopecia Areata.
Wyrwich KW; Winnette R; Bender R; Gandhi K; Williams N; Harris N; Nelson L
Dermatol Ther (Heidelb); 2022 Jan; 12(1):149-166. PubMed ID: 34846634
[TBL] [Abstract][Full Text] [Related]
6. Characterizing the relationships between patient-reported outcomes and clinician assessments of alopecia areata in a phase 2a randomized trial of ritlecitinib and brepocitinib.
Winnette R; Banerjee A; Sikirica V; Peeva E; Wyrwich K
J Eur Acad Dermatol Venereol; 2022 Apr; 36(4):602-609. PubMed ID: 35000236
[TBL] [Abstract][Full Text] [Related]
7. Beyond health-related quality of life: initial psychometric validation of a new scale for addressing the gap in assessing the full range of alopecia areata psychosocial burden.
Gorbatenko-Roth K; Wood S; Johnson M; Wallander I; Nugent J; Hordinsky M
Br J Dermatol; 2023 Jul; 189(1):71-79. PubMed ID: 37267324
[TBL] [Abstract][Full Text] [Related]
8. Health-Related Quality of Life (HRQoL) in alopecia areata patients-a secondary analysis of the National Alopecia Areata Registry Data.
Shi Q; Duvic M; Osei JS; Hordinsky MK; Norris DA; Price VH; Amos CI; Christiano AM; Mendoza TR
J Investig Dermatol Symp Proc; 2013 Dec; 16(1):S49-50. PubMed ID: 24326555
[TBL] [Abstract][Full Text] [Related]
9. Alopecia areata and health-related quality of life: a systematic review and meta-analysis.
Rencz F; Gulácsi L; Péntek M; Wikonkál N; Baji P; Brodszky V
Br J Dermatol; 2016 Sep; 175(3):561-71. PubMed ID: 26914830
[TBL] [Abstract][Full Text] [Related]
10. Comparison of quality of life in patients with androgenetic alopecia and alopecia areata.
Gonul M; Cemil BC; Ayvaz HH; Cankurtaran E; Ergin C; Gurel MS
An Bras Dermatol; 2018; 93(5):651-658. PubMed ID: 30156613
[TBL] [Abstract][Full Text] [Related]
11. Why Finding a Treatment for Alopecia Areata Is Important: A Multifaceted Perspective.
Rodgers AR
J Investig Dermatol Symp Proc; 2018 Jan; 19(1):S51-S53. PubMed ID: 29273107
[TBL] [Abstract][Full Text] [Related]
12. Estimation of health utility values for alopecia areata.
Aggio D; Dixon C; Law EH; Randall R; Price T; Lloyd A
Qual Life Res; 2024 Jun; 33(6):1581-1592. PubMed ID: 38551802
[TBL] [Abstract][Full Text] [Related]
13. Quality of life measurement in alopecia areata. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes.
Chernyshov PV; Tomas-Aragones L; Finlay AY; Manolache L; Marron SE; Sampogna F; Spillekom-van Koulil S; Pustisek N; Suru A; Evers AWM; Salavastru C; Svensson A; Abeni D; Blome C; Poot F; Jemec GBE; Linder D; Augustin M; Bewley A; Salek SS; Szepietowski JC
J Eur Acad Dermatol Venereol; 2021 Aug; 35(8):1614-1621. PubMed ID: 34107093
[TBL] [Abstract][Full Text] [Related]
14. Alopecia areata in children.
Hawit F; Silverberg NB
Cutis; 2008 Aug; 82(2):104-10. PubMed ID: 18792541
[TBL] [Abstract][Full Text] [Related]
15. Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia.
Reid EE; Haley AC; Borovicka JH; Rademaker A; West DP; Colavincenzo M; Wickless H
J Am Acad Dermatol; 2012 Mar; 66(3):e97-102. PubMed ID: 21601948
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life (HRQoL) among patients with alopecia areata (AA): A systematic review.
Liu LY; King BA; Craiglow BG
J Am Acad Dermatol; 2016 Oct; 75(4):806-812.e3. PubMed ID: 27436156
[TBL] [Abstract][Full Text] [Related]
17. Clinical profile and impact on quality of life: seven years experience with patients of alopecia areata.
Al-Mutairi N; Eldin ON
Indian J Dermatol Venereol Leprol; 2011; 77(4):489-93. PubMed ID: 21727697
[TBL] [Abstract][Full Text] [Related]
18. Reliability and validity of a measure to assess the health-related quality of life of women with alopecia areata.
Rees H; Wall D; Bokhari L; Asfour L; Sinclair R
Clin Exp Dermatol; 2023 Jun; 48(6):681-684. PubMed ID: 36806573
[TBL] [Abstract][Full Text] [Related]
19. Reliability and validity assessment of the revised Symptom Checklist 90 for alopecia areata patients in China.
Tan H; Lan XM; Yu NL; Yang XC
J Dermatol; 2015 Oct; 42(10):975-80. PubMed ID: 26072969
[TBL] [Abstract][Full Text] [Related]
20. Assessing quality of life in Alopecia areata patients in China.
Qi S; Xu F; Sheng Y; Yang Q
Psychol Health Med; 2015; 20(1):97-102. PubMed ID: 24628099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
